Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mas
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?
01:00pm, Tuesday, 12'th May 2026
Shares of telehealth provider Hims & Hers Health NYSE: HIMS sold off sharply following disappointing Q1 FY2026 financial results, with shares falling more than 12% in after-hours trading after the com
GLP-1 Wars: Winners & Losers
12:56pm, Tuesday, 12'th May 2026
With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.
Hims & Hers tumbles 15% after earnings miss as GLP-1 transition weighs on results
07:48am, Tuesday, 12'th May 2026
Shares of Hims & Hers Health (HIMS) fell sharply in premarket trading on Tuesday after the telehealth company reported weaker-than-expected first-quarter revenue and a surprise loss. The stock dropped
Novo Nordisk GLP-1 pill launch impresses but price erosion keeps Citi on the sidelines
09:23am, Monday, 11'th May 2026
Shares in Novo Nordisk (NYSE:NVO) drew a cautious reception from Citi following first-quarter results that beat consensus expectations, with the bank raising its target price but retaining a neutral r
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breakin
Global Partners: Valuation Is Favorable (Rating Upgrade)
12:03am, Monday, 11'th May 2026
Global Partners LP is upgraded from hold to buy as valuation and technicals turn favorable after a period of market-driven weakness. GLP's Q1 2026 revenue surged 16% YoY to $5.3B, with operating margi
Global Partners Q1 Earnings Call Highlights
11:12am, Sunday, 10'th May 2026
Global Partners NYSE: GLP reported a sharply higher first-quarter profit and cash flow, with management citing colder weather in the Northeast, stronger wholesale and commercial conditions, and improv
Global Partners LP Common Units (GLP) Q1 2026 Earnings Call Transcript
04:21pm, Friday, 08'th May 2026
Global Partners LP Common Units (GLP) Q1 2026 Earnings Call Transcript
Wells Fargo Downgrades Nike to Equal Weight: GLP-1 Mega-Trend Threatens the Athletic Wear Giant
11:21am, Friday, 08'th May 2026
Wells Fargo just delivered a contrarian gut check to Nike (NYSE:NKE | NKE Price Prediction) stock bulls, downgrading the athletic wear giant to Equal Weight from Overweight and trimming its price targ
New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market
10:30am, Friday, 08'th May 2026
� Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms.
Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market
10:05am, Friday, 08'th May 2026
Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for investors in the Danish pharmaceutical giant. And both UBS and Citi are high
Global Partners LP Reports First-Quarter 2026 Financial Results
08:00am, Friday, 08'th May 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) today reported financial results for the first quarter ended March 31, 2026. CEO Commentary “Solid execution across all operating segm
Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support
04:10pm, Thursday, 07'th May 2026
SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program. Omada w
Retatrutide Black Market: Why Consumers Will Do Anything To Get Eli Lilly's New GLP
12:10pm, Thursday, 07'th May 2026
Eli Lilly's next-generation weight-loss drug, Retatrutide, could hit the shelves soon. Though the treatment has yet to attain FDA approval, demand is already so heavy that consumers are going to the b
